@article{87c6197ccfc542c5bb74672192b14763,
title = "Frequency and Detection of Insulin Infusion Site Failure in the Type 1 Diabetes Exchange Online Community",
abstract = "Insulin infusion site (IIS) failures are a weakness in insulin pump therapy. We examined experience with IIS failures among U.S. individuals with diabetes on insulin pump through survey distributed to the T1D Exchange Online Community. Demographic factors, IIS characteristics, and diabetes-related perceptions were assessed by logistic regression to determine odds of higher (≥1 per month) or lower (<1 per month) reported IIS failure frequency. IIS failures were common; 41.4% reported ≥1 per month. IIS failure is usually detected through development of hyperglycemia rather than pump alarm. No assessed demographic factor or IIS characteristic was predictive; however, higher odds of ≥1 failure per month were associated with feelings of burnout (odds ratios [OR] 1.489 [1.024, 2.165]) and considering pump discontinuation (OR 2.233 [1.455, 3.427]). IIS failures are frequent and unpredictable, typically require hyperglycemia for detection, and are associated with negative perceptions. More should be done toward preventing IIS failures and/or detecting them sooner.",
keywords = "Failure, Insulin infusion set, Insulin infusion site, Insulin pump, Pump malfunction",
author = "Hughes, {Michael S.} and Douvas, {Julia L.} and Madison Layfield-Bryan and Blanco, {Luis E.} and Gray, {John Clark} and Grzegorz Zapotoczny and Juan Espinoza and Wilcox, {John H.} and Lal, {Rayhan A.}",
note = "Funding Information: Creation and distribution of the survey were funded by Diatech Diabetes, Inc. The T1D Exchange is supported through the Leona M. and Harry B. Helmsley Charitable Trust. M.S.H. is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) under Award Number 5K12 DK122550. R.A.L. is supported by a Diabetes, Endocrinology and Metabolism Career Development Grant (1K23 DK122017, P30 DK116074) from NIDDK and has additional research support from JDRF. Funding Information: Creation and distribution of the survey were funded by Diatech Diabetes, Inc. The T1D Exchange is supported through the Leona M. and Harry B. Helmsley Charitable Trust. M.S.H. is supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) under Award Number 5K12 DK122550. R.A.L. is supported by a Diabetes, Endocrinology and Metabolism Career Development Grant (1K23 DK122017, P30 DK116074) from NIDDK and has additional research support from JDRF. Publisher Copyright: {\textcopyright} Copyright 2023, Mary Ann Liebert, Inc., publishers 2023.",
year = "2023",
month = jun,
day = "1",
doi = "10.1089/dia.2023.0005",
language = "English (US)",
volume = "25",
pages = "426--430",
journal = "Diabetes Technology and Therapeutics",
issn = "1520-9156",
publisher = "Mary Ann Liebert Inc.",
number = "6",
}
